Showing results (411-420 of 451) with videos related to

Sort By:
Pageof 46
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2012
Extranodal natural killer/T-cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysisH K Ahn, C Suh, S S Chuang, et al.
Allergy|November 29, 2016
A multicenter study on anaphylaxis caused by peanut, tree nuts, and seeds in children and adolescentsK Jeong, S-Y Lee, K Ahn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOSK Park, J Vansteenkiste, K H Lee, et al.
Physical Review Letters|May 29, 2026
Search for Dark Particles in K_{L}^{0}→γX at the KOTO ExperimentT Wu, Y C Tung, Y B Hsiung, et al.
Physical Review Letters|March 24, 2005
Production of the neutron-rich hypernucleus 10LambdaLi in the (pi-,K+) double charge-exchange reactionP K Saha, T Fukuda, W Imoto, et al.
ESMO Open|September 18, 2025
Identifying predictive markers of head and neck squamous cell carcinoma in an umbrella trial (KCSG HN 15-16 TRIUMPH trial)S Hwang, M H Hong, S H Shin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 13, 2018
The relationship between clinical characteristics including presence of exposed lesions and health-related quality of life (HRQoL) in patients with psoriasis: analysis from the nationwide epidemiologic study for psoriasis in Korea (EPI-PSODE study)S W Youn, J-H Lee, D Y Yu, et al.
ESMO Open|May 13, 2023
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancerS-A Im, A Gennari, Y H Park, et al.
ESMO Open|July 8, 2026
Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after two or more HER2-directed therapiesJ W Kim, Y H Park, S Lee, et al.
ESMO Open|September 25, 2025
Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21)S-A Im, K Park, J Koh, et al.
Pageof 46